Prognosismodifying therapy in patients with CAD: how to optimize treatment?

Authors: Khanyukov A.A., Professor, Doctor of Medical Sciences, Head of the Department of Internal Medicine, State Institution «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine»

According to the materials of the ХІХ National Congress of Cardiologists of Ukraine, September 26-28, Kyiv

In Ukraine, 10.4 million people suffer from arterial hypertension (AH) and 7.7 million from coronary heart disease (CHD). According to statistics, Ukraine ranks first in Europe in terms of the rate of population decline. The lion’s share of deaths is associated with cardiovascular diseases (CVD): every year in our country, 50 thousand heart attacks and 110 thousand strokes are recorded. How to prevent disaster? For an answer to this and other questions, we turned to the head of the Department of Internal Medicine of the 3rd State Institution “Dnepropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Doctor of Medical Sciences, Professor Aleksey Alexandrovich Khanyukov.

Summing up, I want to note that a multidisciplinary approach to individual nosologies has expanded our understanding of the pathogenesis and approaches to the treatment of individual diseases. Today, in daily practice, cardiologists have to work with PPIs, UDCA drugs, and metabolic therapy. Ulsepan, Choludexan, Ripronat can be effective tools for a doctor in achieving the main goal of therapy – reducing the patient’s cardiovascular risk.

Prepared by Maria Marchuk

Download article in PDF (Ru)

Аренда яхты